Predicting Progression to Mild Cognitive Impairment

Ronald C. Petersen; Emily S. Lundt; Terry M. Therneau; Stephen D. Weigand; David S. Knopman; Michelle M. Mielke; Rosebud O. Roberts; Val J. Lowe; Mary M. Machulda; Walter K. Kremers; Yonas E. Geda; Clifford R. Jack

doi:10.1002/ana.25388

Predicting Progression to Mild Cognitive Impairment

Ronald C. Petersen, Emily S. Lundt, Terry M. Therneau, Stephen D. Weigand, David S. Knopman, Michelle M. Mielke, Rosebud O. Roberts, Val J. Lowe, Mary M. Machulda, Walter K. Kremers, Yonas E. Geda, Clifford R. Jack

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.

Original language	English (US)
Pages (from-to)	155-160
Number of pages	6
Journal	Annals of Neurology
Volume	85
Issue number	1
DOIs	https://doi.org/10.1002/ana.25388
State	Published - Jan 2019
Externally published	Yes

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/ana.25388

Cite this

@article{08289a97f0ee494c989eadb99ecde302,

title = "Predicting Progression to Mild Cognitive Impairment",

abstract = "Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.",

author = "Petersen, {Ronald C.} and Lundt, {Emily S.} and Therneau, {Terry M.} and Weigand, {Stephen D.} and Knopman, {David S.} and Mielke, {Michelle M.} and Roberts, {Rosebud O.} and Lowe, {Val J.} and Machulda, {Mary M.} and Kremers, {Walter K.} and Geda, {Yonas E.} and Jack, {Clifford R.}",

note = "Publisher Copyright: {\textcopyright} 2018 American Neurological Association",

year = "2019",

month = jan,

doi = "10.1002/ana.25388",

language = "English (US)",

volume = "85",

pages = "155--160",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Predicting Progression to Mild Cognitive Impairment

AU - Petersen, Ronald C.

AU - Lundt, Emily S.

AU - Therneau, Terry M.

AU - Weigand, Stephen D.

AU - Knopman, David S.

AU - Mielke, Michelle M.

AU - Roberts, Rosebud O.

AU - Lowe, Val J.

AU - Machulda, Mary M.

AU - Kremers, Walter K.

AU - Geda, Yonas E.

AU - Jack, Clifford R.

PY - 2019/1

Y1 - 2019/1

N2 - Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.

AB - Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.

UR - http://www.scopus.com/inward/record.url?scp=85059612078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059612078&partnerID=8YFLogxK

U2 - 10.1002/ana.25388

DO - 10.1002/ana.25388

M3 - Article

C2 - 30521086

AN - SCOPUS:85059612078

SN - 0364-5134

VL - 85

SP - 155

EP - 160

JO - Annals of Neurology

JF - Annals of Neurology

IS - 1

ER -

Predicting Progression to Mild Cognitive Impairment

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this